Universe Pharmaceuticals (UPC) Stock Soars Over 38% After-Hours: Here's What's Going On
Universe Pharmaceuticals Inc. (NASDAQ:UPC) shares climbed 38.64% to $5.92 after the bell on Tuesday.
The stock of the Chinese pharmaceutical producer and distributor closed the regular session at $4.27, down 6.77%, according to Benzinga Pro data.
Eight Investors Disclose Ownership Stakes
The move follows eight Schedule 13G filings submitted to the Securities and Exchange Commission on Tuesday. A Schedule 13G is a short-form beneficial ownership report filed when an investor acquires more than 5% of a public company’s equity securities without the intent to change or influence control of the issuer.
The filings disclosed that British Virgin Islands-registered entities, each wholly owned by a single individual, now hold the bulk of Universe Pharmaceuticals’ Class A shares.
Origin Force Intelligence Limited, controlled by Piao Ye, holds the largest stake at 18.30%, roughly twice the size of any other single filer.
Seven other entities hold stakes ranging from 9.29% to 9.98%.
| Company | Controlled by |
|---|---|
| Horizon Ridge Limited | Shan Xie |
| August Luck Global Limited | Xuefeng Li |
| Star Voyage International Limited | Xuncheng Chen |
| Meridian Prosperous Limited | Shanshan Lu |
| Clever Way Global Limited | Lu Yang |
| Orbis BioCapital Limited | Chunhua Zheng |
| Whitmore Limited | Chengming Tang |
Shareholders To Vote On Reverse Split
In a separate Tuesday filing, Universe Pharmaceuticals also announced its annual general meeting, set for Sept. 30.
Shareholders of record as of Aug. 31 will vote on re-electing five directors and on a proposed 1-for-10 share consolidation.
Shares Trace Back To Patent Acquisition
The disclosed ownership stakes correspond to shares issued as consideration for Universe Pharmaceuticals’ acquisition of Best Praise International Limited, which closed Jun. 30.
The deal, first outlined in a share purchase agreement dated Jun. 17, gave the company five China-based patents covering pharmaceutical compounds and drug-delivery technologies targeting age-related diseases, neurodegenerative conditions, cognitive disorders and cardiovascular applications
Universe Pharmaceuticals issued 4.37 million Class A ordinary shares as consideration for the deal, restricted securities issued under an exemption from standard registration requirements. Following the issuance, the company now has 5.01 million Class A ordinary shares and 16,077 Class B ordinary shares outstanding.
Trading Metrics, Technical Analysis
Universe Pharmaceuticals has a market capitalization of $21.45 million, a 52-week high of $17.96 and a 52-week low of $2.
The Relative Strength Index (RSI) of UPC stands at 41.78.
The stock has risen 21.65% over the past 12 months.
UPC is currently positioned near the lower end of its 52-week range, at about 14.2% of the annual band.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Vintage Tone on Shutterstock.com